LENZ Therapeutics, Inc.
corporate_fare Company Profile
LENZ Therapeutics, Inc. (NASDAQ:LENZ) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for LENZ at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-02, rated 8/10. Across its 14 most recent items scored 7 or higher, the top rating is 8/10, with 9 rated 8 or above. Recent SEC coverage for LENZ spans SCHEDULE 13D/A, 8-K, 10-Q, 10-K.
Recent high-impact activity:
- RA Capital Exits 5% Stake, Dumping 4.18M LENZ Shares in Three Days
- LENZ Misses Q3 Estimates as Revenue Falls 72.9%
- LENZ Cuts 75% of Staff, CEO Out Dec. 1 as 2027 Opex Target Falls to $70-75M
- LENZ Q3 Sales Up 50% but CEO Exits as Reorg Targets 50% Cost Cut
- LENZ Q2 Revenue Hits $5.5M on VIZZ Growth, Loss Widens to $31.9M
Financial Snapshot
Short Interest & Short Volume
5.60 days to coverFINRA reported short interest of 7,069,790 shares in LENZ as of the October 30, 2026 settlement, a 22.3% decrease from the prior period — about 5.6 days to cover at its recent average daily volume. On November 20, 2026, 62.8% of LENZ volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.